FDA Brief

Warning letters Drugs

FDA warning letter to

RemedyRepack, Inc.

High riskIssued May 11, 2023Posted Jun 6, 2023Division of Pharmaceutical Quality Operations I

RemedyRepack, a drug repackager in Indiana, Pennsylvania, failed CGMP, including cleaning and beta-lactam cross-contamination controls.

What happened

FDA inspected RemedyRepack’s drug manufacturing facility in Indiana, Pennsylvania, from November 7 to November 10, 2022. The agency found inadequate cleaning of equipment, including contaminated surfaces and visibly contaminated tablets and capsules, and it said the company lacked chemical testing to confirm cleaning. FDA also found inadequate investigations of broken tablets, packaging processes without adequate validation, and non-penicillin beta-lactam drugs repackaged in the same facility as non-beta-lactam drugs without complete separation.

What FDA found

  1. The company’s written procedures for cleaning and maintaining drug manufacturing equipment were inadequate, and quality checks did not catch contaminated surfaces.

    21 CFR 211.67(b)
  2. The company did not thoroughly investigate unexplained discrepancies or batch failures, such as repeated broken tablets during packaging, and did not determine root causes or corrective actions.

    21 CFR 211.192
  3. The company lacked adequate written production and process control procedures and did not validate its drug packaging processes or qualify packaging equipment.

    21 CFR 211.100(a)
  4. The company did not have separate or defined areas to prevent contamination or mix-ups and repackaged non-penicillin beta-lactam drugs in the same facility as non-beta-lactam drugs.

    21 CFR 211.42(c)

What FDA wants

FDA asks RemedyRepack to correct the violations and respond in writing within 15 working days with corrective actions, including cleaning and investigation assessments, process validation, and beta-lactam separation or decontamination plans. FDA also strongly recommends engaging a qualified CGMP consultant.

Who should pay attention

  • companies that buy repackaged drugs from RemedyRepack
  • pharmacies and patients receiving repackaged tablets or capsules
  • contract manufacturers or repackagers handling beta-lactam and non-beta-lactam drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium